Cancer Ovarian Cancer

Table of Contents

RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Ovarian Cancer Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects

--Top Companies in late stage Ovarian Cancer Projects
--BioNumerik Pharmaceuticals, Inc.
--Access Pharmaceuticals Inc
--Celgene Corporation
--Bristol-Myers Squibb Company
--CuraGen Corp
--Cell Therapeutics Inc
--EntreMed Inc
--Eli Lilly & Co
--GlaxoSmithKline plc
--Genentech Inc
--Merck KGaA
--Marshall Edwards Inc
--Novartis AG
--MGI Pharma, Inc.
--Oasmia Pharmaceutical AB
--Novogen Ltd
--Roche Holdings Ltd
--OSI Pharmaceuticals Inc
--Topotarget A/S
--Telik Inc

--Top Companies in early stage Ovarian Cancer Projects
--Alchemgen Therapeutics Inc.
--Advaxis Inc
--Algeta ASA
--Alethia Biotherapeutics Inc.
--AmpliMed Corporation
--Amgen Inc
--BioWa, Inc.
--Aphios Corporation
--DOR BioPharma Inc
--CuraGen Corp
--Introgen Therapeutics Inc
--Endocyte, Inc.
--MaxCyte, Inc
--Kyowa Hakko Kogyo Co., Ltd.
--Onyvax Limited
--NeoPharm Inc
--Raven biotechnologies, inc.
--Protiva Biotherapeutics Inc
--Yissum Research Development Company
--ViroTarg Pty Ltd

Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Pending Approval Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View